Skip to content

Assessing Efficacy of the Rothman Index

A Pragmatic Randomized Trial Assessing Efficacy of the Rothman Index

Status
Withdrawn
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04403737
Enrollment
0
Registered
2020-05-27
Start date
2021-11-30
Completion date
2023-06-30
Last updated
2022-02-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Inpatients Who Generate at Least Two Rothman Index Scores

Brief summary

This study is designed to assess the efficacy of the Rothman Index in combination with a set of recommended-use protocols to improve rates of mortality and/or rates of discharge to hospice care in hospitalized patients.

Detailed description

The Rothman Index (RI), created by PeraHealth, Inc., is a clinical support system used to recognize the early stages of clinical deterioration. It uses time-updated physiological data (vital signs, lab values, nursing assessments) to calculate a single score that objectively quantifies a patient's condition in real-time. The score is used to detect a patient's declining health and predict risk of decompensation and death. Various risk thresholds exist to describe a patient's status. Medium risk is defined by a 30% reduction in a patient's RI score over 24 hours, high risk is defined by a 40% drop in the RI score over 12 hours, and very high risk is having a score less than or equal to 20 on the RI. Some institutions have created protocols to be followed by providers when an RI risk threshold is reached (such as triggering rapid response team mobilization), however, there are no standardized protocols shared between hospitals, and none which have been rigorously tested to determine whether they effectively reduce mortality and adverse outcomes. This is a randomized controlled trial to determine the efficacy of the Rothman Index and an associated set of RI-triggered recommended-use protocol sin improving rates of mortality and/or discharge to hospice care among inpatients of two hospitals within the Yale New Haven Health System. All inpatients admitted to any unit within the study sites who generate at least 2 RI index scores will be automatically enrolled and randomized to either usual care, in which the patient's RI score is calculated but remains unavailable to providers (and available only to the study team), or to the intervention group in which the RI is calculated and visible to providers who will be encouraged to follow recommended protocols appropriate to the RI risk threshold achieved. The primary outcome is the rates of mortality and/or discharge to hospice care. Secondary outcomes include rates of inpatient mortality, ICU transfer, length of hospital stay, incurred costs, 30 day readmission and mortality rates, and rates of transfer to home.

Interventions

DEVICERothman Index

The Rothman Index score will be calculated and visible to providers. Providers will be encouraged to follow a set of recommended-use protocols in response to different levels of the RI threshold.

Sponsors

PeraHealth
CollaboratorUNKNOWN
Yale University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
SUPPORTIVE_CARE
Masking
SINGLE (Subject)

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Adults inpatients greater than or equal to 18 years of age * Admitted to any inpatient unit at two study sites within the Yale New Haven Health System * Has generated at least 2 Rothman Index scores during the present hospital admission

Exclusion criteria

* Prior admission in which patient was randomized * Patient has opted out of electronic health record consent * Patient in observation status * Patient admitted to hospice service

Design outcomes

Primary

MeasureTime frameDescription
Mortality and/or discharge to hospice careAssessed from the date of randomization to the date of the first documented death or discharge to hospice during patient's current hospitalization, up to 365 daysA composite outcome of mortality and discharge to hospice care as determined by medical record review. Either will be adequate to meet this endpoint.

Secondary

MeasureTime frameDescription
Length of stayAssessed as the number of days from the date of randomization to the first documented discharge, up to 365 daysPatient's length of stay with a start time beginning immediately post-randomization and ending at discharge of the present admission.
Incurred hospital costsAssessed as costs accrued from the date of randomization to the patient's first documented discharge, up to 365 daysHospital costs incurred from post-randomization to discharge, as determined by review of hospital billing records.
ICU transferAssessed from the date of randomization to the date of first documented ICU transfer during patient's current hospitalization, up to 365 daysICU transfer as determined by medical record review.
30 day mortality30 days post-randomizationMortality within 30 days of randomization as determined by medical record review.
Discharge to homeAssessed from the date of randomization to the date of the first document discharge to home, up to 365 daysAs determined by medical record review
Readmission30 days post-randomizationReadmission within 30 days post-randomization as determined by medical record review.

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026